Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas

American Journal of Translational Research

Volumn 7, Issue 1, 2015, Pages 139-152

  Chen, Chi An ^a   Chiang, Ying Cheng ^a   Chang, Ming Cheng ^a   Hu, Yu Hao ^a   You, San Lin ^b   Cheng, Yeu Yao Kevin ^c   Chou, Cheng Yang ^d   Cheng, Wen Fang ^a,e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c MCGILL UNIVERSITY   (Canada)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

DLEC1; E cadherin; Methylation; Ovarian clear cell adenocarcinoma; Ovarian endometrioid adenocarcinoma; RASSF1A; SFRP5

Indexed keywords

DELETED IN LUNG AND ESOPHAGEAL CANCER 1; PAIRED BOX TRANSCRIPTION FACTOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 5; TRANSCRIPTION FACTOR LMX1A; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CAPILLARY ELECTROPHORESIS; DNA METHYLATION; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PHYSICAL SENSITIVITY; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84925344499     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2005; 55: 74-108.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
3. Stuart GC. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol 2003; 90: S8S15.
4. Agarwal R and Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-516.
5. Cancer Registration System Annual Report, Taiwan, Cancer Registration System, Department of Health, 2009. ().
6. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J and Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003; 189: 11201127.
7. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS and Osann K. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006; 108: 521-528.
8. Chiaffarino F, Parazzini F, Bosetti C, Franceschi S, Talamini R, Canzonieri V, Montella M, Ramazzotti V, Franceschi S and La Vecchia C. Risk factors for ovarian cancer histotypes. Eur J Cancer 2007; 43: 1208-1213.
9. Vlahos NF, Kalampokas T and Fotiou S. Endometriosis and ovarian cancer: a review. Gynecol Endocrinol 2010; 26: 213-219.
10. Jimbo H, Yoshikawa H, Onda T, Yasugi T, Sakamoto A and Taketani Y. Prevalence of ovarian endometriosis in epithelial ovarian cancer. Int J Gynaecol Obstet 1997; 59: 245-250.
11. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T and Dimopoulos MA. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006; 102: 285-291.
12. Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A; Gynecologic Cancer Inter Group. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20: 945-952.
13. Egger G, Liang G, Aparicio A and Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457463.
14. Herman JG and Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 20422054.
15. Huang YW, Kuo CT, Stoner K, Huang TH and Wang LS. An overview of epigenetics and chemoprevention. FEBS Lett 2011; 585: 21292136.
16. Shih I, Chen L, Wang CC, Gu J, Davidson B, Cope L, Kurman RJ, Xuan J and Wang TL. Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovar ian carcinogenesis. Am J Obstet Gynecol 2010; 203: 584, e1-e22.
17. Olopade OI and Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 2003; 3: 417-420.
18. Wei SH, Balch C, Paik HH, Kim YS, Baldwin RL, Liyanarachchi S, Li L, Wang Z, Wan JC, Davuluri RV, Karlan BY, Gifford G, Brown R, Kim S, Huang TH and Nephew KP. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 2006; 12: 2788-2794.
19. Kagan J, Srivastava S, Barker PE, Belinsky SA and Cairns P. Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI’s EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer Res 2007; 67: 4545-4549.
20. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G and Brown R. CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer. Cancer Res 2005; 65: 8961-8967.
21. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF and Schorge JO. Promoter Hypermethylation Profile of Ovarian Epithelial Neoplasms. Clin Cancer Res 2005; 11: 5365-5369.
22. Kwong J, Lee JY, Wong KK, Zhou X, Wong DT, Lo KW, Welch WR, Berkowitz RS and Mok SC. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 2006; 8: 268-278.
23. Rosenblatt KA and Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy, The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev 1996; 5: 933-935.
24. Su HY, Lai HC, Lin YW, Chou YC, Liu CY and Yu MH. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer 2008; 124: 387-393.
25. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93: 9821-9826.
26. Chang MC, Chen CA, Hsieh CY, Lee CN, Su YN, Hu YH and Cheng WF. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Biochem J 2009; 424: 449-458.
27. Kurman RJ and Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-443.
28. Yoo CB and Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5: 37-50.
29. Allen NP, Donninger H, Vos MD, Eckfeld K, Hesson L, Gordon L, Birrer MJ, Latif F and Clark GJ. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 2007; 26: 6203-6211.
30. Hesson LB, Cooper WN and Latif F. The role of RASSF1A methylation in cancer. Dis Markers 2007; 23: 73-87.
31. Vos MD, Ellis CA, Bell A, Birrer MJ and Clark GJ. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 2000; 275: 35669-35672.
32. Chan AO, Lam SK and Wong BC. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003; 52: 502506.
33. Graff JR, Greenberg VE, Herman JG, Westra WH, Boghaert ER, Ain KB, Saji M, Zeiger MA, Zimmer SG and Baylin SB. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle’s cell, and poorly differentiated human thyroid carcinoma. Cancer Res 1998; 58: 2063-2086.
34. Ying J, Poon FF, Yu J, Geng H, Wong AH, Qiu GH, Goh HK, Rha SY, Tian L, Chan AT, Sung JJ and Tao Q. DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer 2009; 100: 663-669.
35. Ho CM, Cheng WF, Lin MC, Chen TC, Huang SH, Liu FS, Chien CC, Yu MH, Wang TY and Hsieh CY. Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 2010; 20: 1490-1497.
36. Wang TH, Wang HS and Soong YK. Paclitaxelinduced cell death: where the cell cycle and apoptosis come together? Cancer 2000; 88: 2619-2628.
37. Matei DE and Nephew KP. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol 2010; 116: 195-201.
38. Daigo Y, Nishiwaki T, Kawasoe T, Tamari M, Tsuchiya E and Nakamura Y. Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res 1999; 59: 1966-1972.
39. Litchfield DW. Protein kinase CK2. Structure, regulation and role in cellular decisions of life and death. Biochem J 2003; 369: 1-15.
40. Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC, Lin SP, Lin WC, Lee HY and Yu MH. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 2010; 127: 555-567.
41. Bu XM, Zhao CH, Zhang N, Gao F, Lin S and Dai XW. Hypermethylation and aberrant expression of secreted frizzled-related protein genes in pancreatic cancer. World J Gastroenterol 2008; 14: 3421-3424.
42. Veeck J, Geisler C, Noetzel E, Alkaya S, Hartmann A, Knüchel R and Dahl E. Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis 2008; 29: 991-998.
43. Ricken A, Lochhead P, Kontogiannea M and Farookhi R. Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs. Endocrinol 2002; 143: 2741-2749.
44. Kildal W, Risberg B, Abeler VM, Kristensen GB, Sudbø J, Nesland JM and Danielsen HE. Betacatenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer 2008; 41: 1127-1134.
45. Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC, Rudikoff S, Aaronson SA, Varmus HE and Rubin JS. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc Natl Acad Sci U S A 1997; 94: 6770-6775.
46. Wang K, Li N, Yeung CH, Li JY, Wang HY and Cooper TG. Oncogenic Wnt/β-catenin signalling pathways in the cancer-resistant epididymis have implications for cancer research. Mol Hum Reprod 2013; 19: 57-71.